Results 1 to 10 of about 4,683 (173)

Current appraisal of single inhaler triple therapy in COPD [PDF]

International Journal of COPD, 2018
Brian Lipworth, Chris RuiWen Kuo, Sunny Jabbal Division of Molecular & Clinical Medicine, Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Scotland, UK Abstract: A single inhaler containing ...
Lipworth B, Kuo CRW, Jabbal S
doaj   +11 more sources

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review [PDF]

Respiratory Research, 2019
Background Guidelines recommend that treatment with a long-acting β2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), i.e.
Sue Langham, Jen Lewis, Nick Pooley, Nina Embleton, Julia Langham, MeiLan K. Han, James D. Chalmers   +6 more
doaj   +13 more sources

Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study [PDF]

Therapeutic Advances in Respiratory Disease
Background: The extrafine single inhaler triple therapy (efSITT) containing beclomethasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg has proved to be efficacious in patients with chronic obstructive pulmonary disease (COPD) in randomized ...
Paschalis Steiropoulos, Niki Georgatou, George Krommidas, Konstantinos Bartziokas, Aliki Korkontzelou, Panos Katerelos, Petros Efstathopoulos, Dimosthenis Papapetrou, Stavros Theodorakis, Konstantinos Porpodis   +9 more
doaj   +5 more sources

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD [PDF]

International Journal of COPD, 2021
Jean Bourbeau,1 Mona Bafadhel,2 Neil C Barnes,3,4 Chris Compton,3 Valentina Di Boscio,3 David A Lipson,5,6 Paul W Jones,3,7 Neil Martin,3,8 Gudrun Weiss,3 David MG Halpin9 1Respiratory Epidemiology and Clinical Research Unit, Department of Medicine ...
Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG   +9 more
doaj   +7 more sources

When single-inhaler triple therapy is a preferred option in asthma management? [PDF]

Annals of Thoracic Medicine, 2022
Asthma control is the main goal of management. Unfortunately, most asthma patients with moderate–severe asthma remain uncontrolled despite receiving standard treatment of inhaled corticosteroids (ICS) with long-acting β2 agonists (LABA).
Mohamed S Al-Moamary, Riyad Al-Lehebi, Majdy M Idrees, Mohammed O Zeitouni   +3 more
doaj   +4 more sources

Expert Consensus on Single-Inhaler Triple Therapy for the Treatment of Asthma in Adult Patients. [PDF]

Open Respir Arch
Despite existing guidelines, many patients with asthma do not achieve adequate control of their disease. This is largely due to low adherence to inhaled therapy. Single-inhaler administration may improve this and other aspects of asthma therapy, such as cost-effectiveness.
Serrano CC, Moragón EM, Padilla-Galo A, Aracil CF, Alonso AT, Chica GP, Bastida AP, Falcón AR, Carretero-Gracia JÁ, Soto-Campos JG, Members of the Validation Task Force.   +10 more
europepmc   +5 more sources

Preventing clinically important deterioration with single-inhaler triple therapy in COPD [PDF]

ERJ Open Research, 2018
Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD).
Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson, Gerard Criner   +8 more
doaj   +6 more sources

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials [PDF]

Respiratory Research, 2021
Background In some RCTs comparing triple therapy with dual therapy in COPD, there might be a bias resulting from the use of multiple inhaler devices. This meta-analysis included only RCTs that compared ICS/LABA/LAMA vs.
Huanyu Long, Hongxuan Xu, Jean-Paul Janssens, Yanfei Guo   +3 more
doaj   +5 more sources

Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. [PDF]

Allergy, 2022
AbstractA significant number of patients with asthma remain uncontrolled despite treatment with inhaled corticosteroids (ICS) and long‐acting β2 adrenergic bronchodilators (LABA). The addition of long‐acting antimuscarinic agents (LAMA) can improve the management of asthma in these patients.
Agusti A, Fabbri L, Lahousse L, Singh D, Papi A.   +4 more
europepmc   +4 more sources

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. [PDF]

ERJ Open Res, 2021
UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 µg) improved clinical outcomesversusbudesonide ...
Fenwick E, Martin A, Schroeder M, Mealing SJ, Solanke O, Risebrough N, Ismaila AS.   +6 more
europepmc   +5 more sources